Table 4.
In vivo antimalarial activity against P. berghei (four doses of 100 mg/kg given orally)
| Compound | Vehicle | Activity (%) | Mean survivala (days) | Parasitized RBC on day 30 for mouse no.e: |
% Cured | ||
|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | |||||
| Solithromycin | DMSOb | 99 | >30.0 | 0c | 0c | 0c | 100 |
| DMSO | 99.8 | >30.0 | 0c | 0c | 0c | 100 | |
| HPMC | 99.8 | >30.0 | 0c | 0c | 0c | 100 | |
| Azithromycin | DMSO | 99.1 | >30.0 | 34.3d | 2.20d | 35.3d | 0 |
| HPMC | 99.1 | 24.0 | NA | 74.0d | NA | 0 | |
| Clindamycin | DMSOb | 99 | 15.0 | NA | NA | NA | 0 |
| DMSO | 99.8 | 18.3 | NA | NA | NA | 0 | |
| HPMC | 99.6 | 20.0 | NA | NA | NA | 0 | |
a
Surviving mice were sacrificed on day 30 to determine the presence or absence of parasites.
b
Data are from an initial experiment conducted in 2008.
c
Parasite count by light microscopy (detection limit, 1 parasite per 10,000 erythrocytes; 0.01%).
d
Parasitemia on day 30 as measured by flow cytometry (expressed as the percentage of infected red blood cells).
e
NA, not applicable; these mice did not survive to 30 days. RBC, red blood cells.